Abstract | BACKGROUND: OBJECTIVES: To assess the efficacy and safety of alemtuzumab in the treatment of advanced CTCL. METHODS: A multicentre retrospective analysis was carried out of 39 patients with advanced CTCL treated with alemtuzumab between 2003 and 2013. RESULTS: Thirty-nine patients (median age 62 years, range 20-83) with Sézary syndrome (SS, n = 23) or advanced mycosis fungoides (MF, n = 16) received alemtuzumab 30 mg two to three times per week for a median duration of 12 weeks (range 1-35). Fifteen patients received maintenance therapy for a median duration of 24 weeks (range 6-277). Eleven patients (28%) had transformed disease (MF, n = 10; SS, n = 1). After a median follow-up of 24 months (range 0.3-124), eight patients (21%) were still alive. The overall response rate was 51% in the whole study group (partial response, n = 13; complete response, n = 7); 70% in patients with SS and 25% in patients with MF (P = 0.009). The median time to progression was 3.4 months (range 0.4-42). Six patients (15%; SS, n = 5; MF, n = 1) remained progression free for > 2 years (median 56 months, range 28-117). Five patients experienced cutaneous large T-cell transformation during alemtuzumab treatment and one patient developed primary cutaneous large B-cell lymphoma. Twenty-four patients (62%) had a grade three or higher infectious adverse event and 10 (26%) a haematological toxicity, which led to treatment discontinuation in 17 cases (44%) and death in two (5%). CONCLUSIONS:
Alemtuzumab may induce long-term remission in SS but seems ineffective in MF and transformed CTCL.
|
Authors | A de Masson, P Guitera, P Brice, I Moulonguet, F Mouly, J-D Bouaziz, M Battistella, I Madelaine, J Roux, C Ram-Wolff, J-M Cayuela, H Bachelez, A Bensussan, L Michel, M Bagot |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 170
Issue 3
Pg. 720-4
(Mar 2014)
ISSN: 1365-2133 [Electronic] England |
PMID | 24438061
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | © 2014 British Association of Dermatologists. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Alemtuzumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Female
- Humans
- Injections, Intradermal
- Injections, Intravenous
- Long-Term Care
- Lymphoma, T-Cell, Cutaneous
(drug therapy)
- Male
- Middle Aged
- Mycosis Fungoides
(drug therapy)
- Retrospective Studies
- Skin Neoplasms
(drug therapy)
- Young Adult
|